NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Hims & Hers Health
HIMS
US Stock MarketDetailed Quotes
OTLK Outlook Therapeutics
- 1.480
- -0.040-2.63%
Close Feb 25 16:00 ET
- 1.630
- +0.150+10.14%
Post 20:01 ET
47.39MMarket Cap-0.60P/E (TTM)
1.540High1.441Low412.07KVolume1.540Open1.520Pre Close612.30KTurnover1.75%Turnover RatioLossP/E (Static)32.02MShares12.85052wk High-0.94P/B34.92MFloat Cap0.87052wk Low--Dividend TTM23.60MShs Float219.200Historical High--Div YieldTTM6.55%Amplitude0.870Historical Low1.485Avg Price1Lot Size
About Outlook Therapeutics Company
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Company Profile
SymbolOTLK
Company NameOutlook Therapeutics
Listing DateJun 13, 2016
Founded2010
CEOMr. Lawrence A. Kenyon
MarketNASDAQ
Employees23
Fiscal Year Ends09-30
Address111 South Wood Avenue,Unit 100
CityIselin
ProvinceNew Jersey
CountryUnited States of America
Zip Code08830
Phone1-609-619-3990
Company Executives
- Name
- Position
- Salary
- Lawrence A. Kenyon
- Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Principal Accounting Officer and Director
- 634.60K
- Jeff Evanson
- Chief Commercial Officer
- 768.03K
- Faisal G. Sukhtian
- Chairman of the Board
- 113.00K
- Kurt J. Hilzinger
- Independent Director
- 95.00K
- Ralph H. Thurman
- Lead Independent Director
- 242.50K
- Dr. Julia A. Haller, M.D.
- Independent Director
- 79.00K
- Dr. Gerd U. Auffarth, M.D.
- Independent Director
- 79.00K
- Yezan Munther Haddadin
- Independent Director
- 110.00K
- Andong Huang
- Independent Director
- 75.00K
- Julian S. Gangolli
- Independent Director
- 112.50K